News

Innovative W1 REGEN Cold Laser: A Game Changer in Recovery

Innovative W1 REGEN Cold Laser: A Game Changer in Recovery

MATELASER Debuts the Revolutionary W1 REGEN Series

MATELASER, INC. has unveiled its innovative W1 REGEN Series, introducing a new era in portable cold laser technology tailored for deep-tissue healing. This groundbreaking device, which includes the W1 REGEN and its more advanced variant, W1 REGEN ULTRA, boasts a remarkable weight of just 24 grams per module. As the lightest wearable medical-grade cold laser available, it is designed to bring pain relief, recovery, and enhanced blood circulation directly into the hands of users at their convenience.

Revolutionizing Pain Relief with Precision

At the heart of the W1 REGEN Series lies patented VCSEL laser technology, utilizing dual wavelengths of 660nm and 810nm. Delivering a laser output of up to 70mW per module, this system empowers users with clinical-grade precision for therapeutic interventions. Notably, the device incorporates a 1000Hz high-frequency pulsed mode, enhancing cellular activation while ensuring a comfortable, drug-free experience.

Dr. Jack Biesenbach, co-founder of MATELASER, emphasizes the mission behind the W1 REGEN Series: "Our goal is to make professional-grade laser therapy accessible to everyone, transforming clinical practices into everyday wellness solutions. Users can manage their healing and performance effectively anytime, anywhere. "

Next-Generation Laser Therapy

What sets the W1 REGEN apart from traditional LED-based devices is its focused VCSEL laser beams designed to penetrate deeper into muscles, joints, and nerves. With a specialized 25° divergence angle, the device achieves optimal energy delivery, facilitating enhanced tissue regeneration and pain relief that surpasses the limitations of standard LED therapies.

W1 REGEN Model Features

The W1 REGEN comes equipped with a single module specifically designed for targeted pain relief and muscle recovery with 70mW output. In contrast, the W1 REGEN ULTRA comprises four synchronized modules, providing a total output of 280mW. This advanced setup allows for multi-zone treatment, making it perfect for larger areas like the lower back or both knees simultaneously. Each model offers three customizable therapy modes: Continuous, 10Hz, and 1000Hz Pulsed, adapted for unique treatment goals and smart accessories.

Accessible Clinical-Grade Laser Therapy

The launch of the W1 REGEN Series represents a significant milestone in democratizing clinical laser therapy for personal use. Grounded in MATELASER's extensive research in photobiomodulation—the study of light in cellular repair—the device is engineered to offer hospital-level precision tailored for daily life applications. Improvement in energy efficiency ensures a stable output without risking overheating, even through extended sessions.

According to Dr. Biesenbach, "Every aspect of our W1 REGEN Series, from wavelength consistency to power density, has been meticulously validated against clinical standards. This ensures that we deliver a wearable laser that meets both therapeutic efficacy and consumer convenience."

Advantages of the W1 REGEN Series

The W1 REGEN is designed to seamlessly fit into contemporary lifestyles, offering numerous health benefits, including:

  • Drug-free pain relief for chronic or post-exercise discomfort.
  • Accelerated recovery following workouts or physiotherapeutic sessions.
  • Safe rehabilitation post-surgery.
  • Promotion of relaxation and balance in the nervous system through gentle photobiomodulation.

The ULTRA model includes an efficient smart charging dock that powers all modules concurrently, facilitating effortless full-body therapy sessions. Whether it’s athletes looking to enhance recovery, office workers in need of quick relief, or seniors managing chronic pain, the W1 REGEN Series provides professional outcomes in an easily accessible format.

Crowdfunding Launch on Kickstarter

Anticipation builds around the Kickstarter launch scheduled for November 18, where early backers will enjoy exclusive discounts and limited-edition perks for this revolutionary wearable laser therapy system.

About MATELASER, INC.

Headquartered in Miami, MATELASER, INC. is an FDA-certified firm specializing in high-power laser technologies aimed at delivering effective and safe therapeutic solutions. With rich expertise in photobiomodulation, MATELASER is committed to making advanced laser therapy accessible to daily users worldwide.

Frequently Asked Questions

What is the W1 REGEN Series?

The W1 REGEN Series consists of advanced wearable medical-grade cold lasers designed for deep tissue healing, pain relief, and enhanced circulation.

How does the W1 REGEN work?

It utilizes patented VCSEL laser technology with dual wavelengths, delivering precise laser output that activates cellular functions safely and effectively.

Who can benefit from using the W1 REGEN?

It is suitable for a wide range of users, including athletes, office workers, and older adults seeking drug-free pain relief and faster recovery.

What treatments does the W1 REGEN offer?

It offers customizable therapy modes and is effective for localized pain relief, muscle recovery, and even post-surgery rehabilitation.

When will the W1 REGEN be available for purchase?

The kickstarter launch on November 18 will allow early backers exclusive access to purchase the W1 REGEN Series.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PJM Prepares to Tackle Winter Power Demands

Updated Category News Views 97

Eyeing the Season Ahead The chill in the air isn't just meteorological; there's a business note to notice every winter in PJM's sprawling territory. With power supplies robust yet stretched thin, PJM is bracing to navigate another demanding cold season. They’ve announced they have 182,426 MW of operational capacity nipping at the heels of a projected peak demand of...

Continue Reading
Bowling Makes a Strike at Macy's 100th Parade in NYC

Updated Category News Views 41

Rolling with Tradition: Bowling at Macy's Parade Back in the day, bowling wasn't exactly the sport making headlines. But times, they change. Here we are in the thick of things, witnessing Go Bowling getting its moment in the spotlight during the historic 100th Macy's Thanksgiving Day Parade®. It's not about raking in the dough or hitting some stocks; it’s about...

Continue Reading
RadianX Grabs $9M for Perovskite Solar Push

Updated Category News Views 105

RadianX Making Waves with New Funding Diving headfirst into the clean energy scene, RadianX has snagged a hefty $9 million in fresh funding. Now, this isn't some chump change. We're talking about a solid push to get their perovskite photovoltaic modules off the ground and into widespread use. They've got financial backing from big players like SOSV and Twynam, spearheaded...

Continue Reading
Faith Leaders Reject Dominion-NextEra $67B Merger

Updated Category News Views 108

Voices Raised Against a Corporate Giant Today, outside the drab halls of the Virginia State Corporation Commission (SCC), a group of faith leaders drew a line in the sand against a looming energy giant. The $67 billion move to merge Dominion Energy with NextEra Energy ignited their rallying cry. Phooey to sacrificing community well-being for corporate greed, they shouted....

Continue Reading
METLEN Posts Record 9-Month Revenue in 2026

Updated Category News Views 138

Record Revenue Achievement Oh boy, METLEN just broke the bank with its nine-month trading update for 2026, hitting €6.2 billion in revenue. It's the highest they've ever seen for this period. A 21% jump from the previous €5.1 billion in 9M2025—now that's saying something in these unpredictable markets. Drilling down, the company’s business units showed they can...

Continue Reading
Yesway's Festive Campaign Drives Holiday Sales Surge

Updated Category News Views 83

A Holiday Extravaganza in Convenience Retail Here's the deal: Yesway's pulling out all the stops this holiday season, and they're not just offering cheap hotdogs or knocking a nickel off the gas. They're diving into some fiery New Mexico-inspired festivities with their latest campaign, “Red or Green…or Christmas?” It's like a candy cane made of salsas—just in time...

Continue Reading
Cardinal Health Surges with Increased EPS Outlook

Updated Category News Views 132

Cardinal Health's Towering Numbers and Raised Outlook Holy moly, Cardinal Health is strutting out of the gate like they mean business. Their first quarter for fiscal year 2027 showed revenue hitting a hefty $67.5 billion—up 5% from last year. If you're holding NYSE:CAH, you might be grinning ear to ear right now. Cardinal didn’t just squeeze out more revenue; they saw...

Continue Reading
Tripadvisor Faces Investigation Over Securities Violations

Updated Category News Views 58

Tripadvisor's Stock Dive: Investor Panic or Opportunity? Woah, if you had a stake in Tripadvisor (NASDAQ: TRIP) recently, you know it hasn't been a walk in the park. Shares took a nosedive of over 20% on November 5, 2026, after they unveiled a frightening $313.1 million net loss for the third quarter. What stirred the pot, you ask? Well, toss in a goodwill impairment...

Continue Reading
Aberlour Elevates U.S. Market with New Whisky Launches

Updated Category News Views 55

Aberlour's Bold U.S. Expansion Aberlour isn't just gently knocking on the U.S. market's door; they're making a hefty entry with a couple of heavy hitters—a 14-Year-Old and a 21-Year-Old single malt Scotch whisky. And trust me when I say, they've got their eyes on being top-shelf material. It seems they're not tiptoeing into the States; they're striding in with...

Continue Reading
GradBridge Unveils HQ to Bolster Fintech Growth

Updated Category News Views 201

Milestone Moment for GradBridge's Expansion Picture this: a fintech upstart in Delaware, making waves with its innovative approach to student lending. That's exactly what's happening with GradBridge as they open their new headquarters at Newark's Iron Hill Corporate Center. This isn't just about cutting a ribbon; it's a declaration that they're serious about shaking...

Continue Reading

Top 5 Most Recently Viewed Articles

Savara Inc. Investors Urged to Join Class Action Lawsuit

Updated Category News Views 138

Legal Action Opportunities for Savara Inc. Investors Attention all investors in Savara Inc. (NASDAQ: SVRA)! If you've faced substantial losses recently, this is an important time to consider potential legal action. Bronstein, Gewirtz & Grossman LLC, a recognized legal firm, is here to guide you through the class action lawsuit against Savara Inc., which is acting in the...

Continue Reading
Corvus Pharmaceuticals Showcases Soquelitinib Trial Success

Updated Category News Views 165

Corvus Pharmaceuticals Highlights Key Data on Soquelitinib Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), recognized for its pioneering role in clinical-stage biopharmaceuticals, is set to present important findings from its Phase 1/1b trial involving soquelitinib, a promising treatment for T cell lymphoma. This presentation will occur at a distinguished oral session during...

Continue Reading
Exciting New Alliance Between Domino's and DoorDash Unveiled

Updated Category News Views 240

Exciting Partnership Announcement Domino's Pizza Inc. (NASDAQ: DPZ), the leading pizza company globally, has officially partnered with DoorDash, a robust local commerce platform in North America. This significant collaboration aims to expand Domino's customer reach through DoorDash's extensive marketplace, delivering a win-win scenario for both entities. Key Highlights of...

Continue Reading
D.Law Named One of LA's Top Three Workplaces by LABJ

Updated Category News Views 126

D.Law Celebrated as a Leading Workplace in Los Angeles D.Law, a prominent California employment law firm, is thrilled to announce that it has achieved the distinction of being the #3 Best Place to Work in the mid-size company category as recognized by the Los Angeles Business Journal (LABJ). Remarkably, D.Law stands out as the only law firm among the top five awardees,...

Continue Reading
NABR Celebrates CITES Decision on Long-Tailed Macaques Trade

Updated Category News Views 316

NABR Commends CITES Decision on Long-Tailed Macaques The National Association for Biomedical Research (NABR) is pleased to announce the recent decision of the CITES Standing Committee, which opted not to implement a trade suspension on long-tailed macaques. This development marks a significant moment for the international research community, recognizing the importance of...

Continue Reading